SAA1 gene polymorphisms in osteoporosis patients

Area of Science:

• Genetics
• Metabolic Diseases
• Bone Health

Background:

• Serum amyloid A (SAA1) is an apolipoprotein crucial for glucose and lipid homeostasis.
• SAA1 polymorphisms are implicated in cardiovascular diseases like myocardial infarction and coronary artery disease (CAD).
• The association between SAA1 gene variations and osteoporosis susceptibility remains largely unexplored.

Purpose of the Study:

• To investigate the relationship between specific Serum amyloid A (SAA1) gene single-nucleotide polymorphisms (SNPs) and osteoporosis risk.
• To evaluate the influence of SAA1 gene polymorphisms on clinical parameters in osteoporosis patients.

Main Methods:

• A hospital-based case-control study involving 300 osteoporosis patients and 350 controls.
• Genotyping of three SAA1 SNPs (rs183978373, rs12218, and rs10832915) using MALDI-TOF MS.
• Haplotype analysis was performed to assess combined SNP effects.

Main Results:

• No significant association was found for SAA1 SNPs rs183978373 and rs12218 with osteoporosis.
• The SAA1 rs10832915 polymorphism was significantly associated with an increased risk of osteoporosis in the studied Chinese population.
• No significant correlation was observed between rs10832915 genotypes and clinical parameters like BMI, lipid profiles, or T-score.
• The ATT haplotype of SAA1 was significantly correlated with a decreased risk of osteoporosis.

Conclusions:

• The SAA1 rs10832915 polymorphism is associated with osteoporosis risk in the Chinese population.
• SAA1 gene haplotypes, specifically ATT, show a correlation with reduced osteoporosis risk.
• Further large-scale studies are recommended to validate these findings on SAA1 and osteoporosis.